Nisa Investment Advisors LLC Has $38,000 Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

Nisa Investment Advisors LLC raised its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) by 14,125.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,820 shares of the company’s stock after purchasing an additional 8,758 shares during the period. Nisa Investment Advisors LLC’s holdings in Sutro Biopharma were worth $38,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Sutro Biopharma in the third quarter valued at about $113,000. Exchange Traded Concepts LLC raised its position in shares of Sutro Biopharma by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 35,856 shares of the company’s stock valued at $154,000 after buying an additional 9,092 shares in the last quarter. Barclays PLC lifted its holdings in shares of Sutro Biopharma by 40.7% during the 3rd quarter. Barclays PLC now owns 62,579 shares of the company’s stock worth $217,000 after acquiring an additional 18,093 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Sutro Biopharma by 20.9% during the 3rd quarter. Los Angeles Capital Management LLC now owns 68,324 shares of the company’s stock worth $237,000 after acquiring an additional 11,800 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Sutro Biopharma by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 261,451 shares of the company’s stock worth $907,000 after acquiring an additional 8,633 shares in the last quarter. 96.99% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Nicki Vasquez sold 12,185 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $5.00, for a total transaction of $60,925.00. Following the completion of the transaction, the insider now directly owns 12,803 shares of the company’s stock, valued at approximately $64,015. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by insiders.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $3.77 on Tuesday. The business has a 50 day moving average of $4.45 and a 200-day moving average of $3.88. The company has a market capitalization of $235.40 million, a P/E ratio of -2.12 and a beta of 0.95. Sutro Biopharma, Inc. has a 1 year low of $2.01 and a 1 year high of $6.13.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Monday, March 25th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $1.24. The firm had revenue of $113.72 million for the quarter, compared to analyst estimates of $12.16 million. Sutro Biopharma had a negative net margin of 69.47% and a negative return on equity of 71.42%. Equities analysts anticipate that Sutro Biopharma, Inc. will post -3.18 EPS for the current year.

Analyst Ratings Changes

STRO has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. HC Wainwright reduced their price objective on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th. Truist Financial lowered their target price on Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. Oppenheimer restated an “outperform” rating and issued a $10.00 price target on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price target (down from $12.00) on shares of Sutro Biopharma in a report on Wednesday, April 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sutro Biopharma presently has a consensus rating of “Buy” and an average target price of $12.57.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.